Mendus to participate in multiple investor and industry conferences in September

Advertisement

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:


H.C. Wainwright 25th Annual Global Investment Conference

Advertisement

New York, USA, September 11-13, 2023

Mendus CEO Erik Manting will participate and present a Company Update at the conference:

https://hcwevents.com/annualconference/


Pareto Securities’ Annual Healthcare Conference

Stockholm, Sweden, September 14, 2023

Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference:

https://paretosec.com/updates/events-and-conferences/


CICON23 – International Cancer Immunotherapy Conference

Milan, Italy, September 20-23, 2023

Mendus to present preclinical and clinical data on the mode of action of its lead clinical program vidicencel

http://www.cancerimmunotherapyconference.org/


Nordic Conference and Opening Ceremony of NorthX Innovation Hub

Matfors, Sweden, September 27-28, 2023

Mendus Board member Hans Preusting will participate at the event:

https://nxbio.confetti.events/

ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/


FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: [email protected]

INVESTOR RELATIONS
Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: [email protected]

MEDIA RELATIONS
Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: [email protected]

Attachment

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.